Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLLX4 Ofatumumab Induction and Maintenance in Elderly Poor-Risk CLL Patients Undergoing Allogeneic Transplantation
2012-001947-31Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Technische Universität Dresden. Primary endpoints: Response rate after induction therapy and MRD-negative relapse-free survival at 14 months. Started Jul 2012; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-001947-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001947-31.